Saturday 17 October 2026
Export ABVX’s income statement to Excel — free account
Abivax SA Sponsored ADR
ABVX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 98.8%, free cash flow fell 48.3% and total debt fell 98.5%, each against the same quarter a year earlier.
87.78
4.60
−4.98%
Follow ABVX
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 8.00 | 6.53 | 4.77 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | 11.60 | 17.02 | 148.83 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 34 | 136 | 69 | 69 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | (23) | (39) | (46) | (54) | (64) | (160) | (191) | (374) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | — | (19) | (34) | (43) | (49) | (64) | (160) | (191) | (380) | |||||
| Depreciation | — | — | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (1.83) | (2.81) | (2.99) | (2.92) | (3.35) | (3.04) | (3.03) | (5.46) | |||||
| Cash flow | — | — | (1.69) | (2.52) | (2.38) | (3.22) | (2.98) | (2.44) | (2.64) | (2.62) | |||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (0.02) | (0.01) | (0.01) | 0.00 | |||||
| Free cash flow | — | — | (1.69) | (2.52) | (2.38) | (3.22) | (2.99) | (2.45) | (2.66) | (2.62) | |||||
| Book value | — | — | 3.23 | 1.09 | 0.40 | 1.95 | 0.40 | 4.93 | 0.70 | 7.41 | |||||
| Shares, m | — | — | 10 | 12 | 14 | 17 | 19 | 43 | 63 | 70 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (17) | (31) | (34) | (54) | (57) | (105) | (167) | (182) | ||||
| Capex | — | — | (1) | (1) | (1) | (2) | 0 | 0 | (1) | 0 | |||||
| Free cash flow | — | — | (17) | (31) | (34) | (54) | (57) | (105) | (167) | (182) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 13 | 2 | 14 | 49 | 4 | 234 | 83 | 552 | ||||
| Total debt | — | — | 12 | 23 | 42 | 61 | 41 | 60 | 104 | 2 | |||||
| Net debt | — | — | (2) | 12 | 6 | (8) | 13 | (223) | (60) | (607) | |||||
| Shareholders’ equity | — | — | 33 | 13 | 6 | 33 | 8 | 212 | 44 | 515 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | 0.00 | (57.22) | (58.92) | (45.95) | (62.40) | (73.76) | (66.21) | (86.11) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (208.88) | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | 0.00 | (148.81) | (451.99) | (254.34) | (317.63) | (145.55) | (148.96) | (136.07) | |||||
Negative figures in brackets.
Fundamentals updated 2 Oct 2026
Charts ten years each
Abivax SA Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CAI Caris Life Sciences,�Inc. | $9.0B | 81.3× | 163× | +45.38% (above 0%: growing) | n/m | +8.47% (above 0%: growing) | 68.10% | 10.21% | Compare |
| CYTK Cytokinetics, Incorporated | $8.9B | — (loss-making) | — (loss-making) | −57.13% (below 0%: shrinking) | n/m | −24.02% (below 0%: shrinking) | 80.46% | (625.95%) | Compare |
| PTGX Protagonist Therapeutics, Inc. | $8.8B | 106× | 25.0× | +3,749.17% (above 0%: growing) | n/m | +839.65% (above 0%: growing) | 100.00% | 74.37% | Compare |
| TGTX TG Therapeutics, Inc. | $8.6B | 17.8× | 29.4× | +70.27% (above 0%: growing) | −73.68% (below 0%: shrinking) | +427.05% (above 0%: growing) | 82.86% | 9.02% | Compare |
| AXSM Axsome Therapeutics, Inc. | $8.5B | — (loss-making) | — (loss-making) | +45.54% (above 0%: growing) | n/m | −2.98% (below 0%: shrinking) | 93.79% | (22.73%) | Compare |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.3B | — (loss-making) | — (loss-making) | +171.02% (above 0%: growing) | n/m | −15.43% (below 0%: shrinking) | 100.00% | (226.03%) | Compare |
| ABVX Abivax SA Sponsored ADR | $8.1B | — (loss-making) | — | — | n/m | −48.28% (below 0%: shrinking) | 0.00% | 0.00% | |
| SYRE Spyre Therapeutics, Inc. | $7.4B | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −50.07% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| IONS Ionis Pharmaceuticals, Inc. | $7.3B | — (loss-making) | — (loss-making) | −40.73% (below 0%: shrinking) | n/m | +299.29% (above 0%: growing) | 98.98% | (38.18%) | Compare |
| Median of peers | $8.5B | 81.3× | 29.4× | +45.46% | — | +2.75% | 88.33% | (11.36%) |
Abivax SA Sponsored ADR (ABVX) key facts
- Abivax SA Sponsored ADR (ABVX) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
- As of October 16, 2026, ABVX traded at $87.78, a market capitalization of $8.1 billion.
- Return on equity was −136.1% and debt-to-equity 0.00.